All In Biotech

Drug Trial Radar · NCT06374823

Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke

The Impact of Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke Patients: A Prospective, Multicenter, Open-label, Randomized Controlled Study

Last checked: Nov 20, 2026Latest source record: Apr 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 342 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

342

Planned (sponsor's estimate)

Start

May 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Capital Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Normal saline (0.9% sodium chloride), a classical crystalloid solution, is widely used to maintain fluid balance, volume resuscitation and dilute drugs during clinical practice. However, the chloride concentration of normal saline (154mmol/L) is much higher than human plasma, and a large amount of infusion may lead to iatrogenic hyperchloremia in ICU patients. In contrast, the concentrations of Multiple electrolytes II is more similar to those of plasma and is considered to be a better fluid choice than normal saline.

Conditions

  • Critical Care
  • Hyperchloremia
  • Hemorrhagic Stroke

Interventions

  • Multiple ElectrolyteDrug

    Patients who are randomized to multiple electrolyte group will be receiving Multiple Electrolytes injection II for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.

  • Normal SalineDrug

    Patients who are randomized to normal saline group will be receiving Sodium Chloride injection for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HyperchloremiaTime frame: At 24 hours, 48 hours, 72 hours after enrollment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Shijitan Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.